New drug targets Hard-to-Treat cancers with MET mutations

NCT ID NCT03993873

Ongoing Disease control Sponsor: Turning Point Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will take the drug by mouth, and researchers will monitor side effects and how the drug moves through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung gastric cancer gastric neoplasm Liver Neoplasms lung neoplasm metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR MET GENE ALTERATIONS METASTATIC SOLID TUMORS

Contacts and locations

Locations

Local Institution - 2101

Houston, Texas, 77030-4009, United States
Local Institution - 2102

La Jolla, California, 92093, United States
Local Institution - 2103

St Louis, Missouri, 63110, United States
Local Institution - 2104

Toledo, Ohio, 43614, United States
Local Institution - 2105

Denver, Colorado, 80218, United States
Local Institution - 2106

Ann Arbor, Michigan, 48109, United States
Local Institution - 2107

Boston, Massachusetts, 02114, United States
Local Institution - 2108

Orange, California, 92868, United States
Local Institution - 2109

Boston, Massachusetts, 02215, United States
Local Institution - 2111

Chicago, Illinois, 60637, United States
Local Institution - 2112

Fairfax, Virginia, 22031, United States
Local Institution - 2113

Detroit, Michigan, 48202, United States
Local Institution - 4101

Madrid, 28050, Spain
Local Institution - 4102

Pamplona, 31008, Spain
Local Institution - 4103

Madrid, 28040, Spain
Local Institution - 4104

Madrid, 28036, Spain
Local Institution - 4201

Lyon, 69008, France
Local Institution - 4202

La Tronche, Auvergne-Rhône-Alpes, 38700, France
Local Institution - 4203

Saint-Mandé, Val-de-Marne, 94160, France
Local Institution - 4204

Villejuif, Val-de-Marne, 94805, France
Local Institution - 6301

Seoul, Seoul-teukbyeolsi [Seoul], 06351, South Korea
Local Institution - 6302

Seoul, 120-752, South Korea
Local Institution - 6303

Seoul, 03080, South Korea
Local Institution - 6304

Seoul, 05505, North Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.